ALISO VIEJO, Calif., March 1 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX), today announced that it has entered into an agreement with Spear Pharmaceuticals, Inc. for rights to commercialize Refissa®, a prescription-based topical tretinoin cream used to diminish fine wrinkles and fade irregular pigmentation due to sun damage. Valeant will pay Spear a $12 million upfront payment and the two companies will share net profits. Valeant will book sales and use its dermatology sales force to promote Refissa® to dermatologists nationwide. The Refissa® family of products had total sales of approximately $5 million in 2009.
